Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730094 | 0.92 | SCN9A (0.45) | PTGS2PTGS1KMOSCN9ANAAA | |
| SCHEMBL6722847 | 0.87 | KMO (0.45) | PTGS2PTGS1GLO1KMOSCN9A | |
| SCHEMBL6721590 | 0.86 | KMO (0.43) | PTGS2PTGS1GLO1KMOSCN9A | |
| SCHEMBL6721414 | 0.84 | KMO (0.48) | PTGS2PTGS1KMOSCN9A | |
| SCHEMBL7042025 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1GLO1KMOSCN9A | |
| SCHEMBL6723197 | 0.82 | MALT1 (0.42) | PTGS2PTGS1GLO1KMO | |
| SCHEMBL6722774 | 0.82 | PTGS2 (0.54) | PTGS2PTGS1GLO1KMOADORA2A | |
| SCHEMBL6718600 | 0.82 | GLO1 (0.42) | PTGS2PTGS1GLO1KMO | |
| SCHEMBL6729798 | 0.82 | KCNA5 (0.41) | PTGS2PTGS1GLO1KMOSCN9A | |
| SCHEMBL6723509 | 0.82 | FEN1 (0.40) | PTGS2PTGS1GLO1KMONAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885GLO1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.